Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics
Advanced Healthcare Materials · 2025-06 · 14 (16)
DOI: 10.1002/adhm.202501015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 15.05.2025. Verfasst von Pengfei Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, School of Interdisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Labo…. Hauptthemen laut MEDLINE: Needles, Nucleic Acids, Drug Delivery Systems, Microinjections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 263 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research & Development Program of China, Fundamental Research Funds for the Central Universities of China.
Abstract (Originalsprache)
Nucleic acid therapy demonstrates great potential in cancer treatment, infectious disease prevention, and vaccine development due to its advantages, such as rapid production, long‐lasting effects, and high target specificity. Although nucleic acid therapy is considered ideal for the development of novel therapeutic strategies, its clinical application still faces numerous challenges, including the lack of efficient delivery systems, insufficient drug formulation stability, and the limitations imposed by the skin barrier on drug dosage delivery. Microneedles, as an innovative transdermal drug delivery technology, can penetrate the stratum corneum and directly access the skin's microcirculation, enabling the efficient delivery of genes and drugs. This technology offers several advantages, such as ease of operation, minimally invasive and painless application, and high safety. Combining microneedle technology with nucleic acid therapy fully leverages the strengths of both approaches, significantly enhancing therapeutic efficacy and bioavailability while maximizing treatment potential. This review explores the application prospects and advantages of combining microneedle delivery systems with nucleic acid therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science, School of Interdisciplinary Science, Aerospace Center Hospital, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical, Molecule Science and Pharmaceutics Engineering, Bei…
- School of Medical Engineering, School of Interdisciplinary Science, Affiliated Zhuhai People's Hospital, Beijing Institute of Technology, Zhuhai, 519088, P.R. China.
- Advanced Technology Research Institute, Beijing Institute of Technology, Jinan, 250100, P.R. China.
- Zhengzhou Research Institute, Beijing Institute of Technology, Zhengzhou, 450040, P. R. China.
- Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Erqi, Zhengzhou, 450000, P. R. China.
- Department of Biology, School of Sciences and Humanities, Nazarbayev University, Astana, 010000, Kazakhstan.
ORCID-Profile: Yuanyu Huang
Förderung
- National Natural Science Foundation of China
- National Key Research & Development Program of China
- Fundamental Research Funds for the Central Universities of China
- Beijing Municipal Science & Technology Commission
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wu, P., Zhang, T., Zhao, D., Xie, Y., Huang, D., Li, Z., & Huang, Y. (2025). Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics. Advanced Healthcare Materials, 14(16). https://doi.org/10.1002/adhm.202501015
Vancouver
Wu P, Zhang T, Zhao D, Xie Y, Huang D, Li Z, et al. Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics. Advanced Healthcare Materials. 2025;14(16). doi:10.1002/adhm.202501015
BibTeX
@article{Wu2025,
author = {Wu, Pengfei and Zhang, Tian and Zhao, Deyao and Xie, Yingqiu and Huang, Dong and Li, Zhihong and Huang, Yuanyu},
title = {Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {16},
doi = {10.1002/adhm.202501015}
}
EUVIMED